SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity

Michael Joyce, Wei‐Hung Chen, Rajeshwer S. Sankhala, +57

Cell Reports

A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates

Michael Joyce, Hannah A. D. King, Inès Lakhal-Naouar, +55

Science Translational Medicine

Simian Immunodeficiency Virus (SIV)-Specific Chimeric Antigen Receptor-T Cells Engineered to Target B Cell Follicles and Suppress SIV Replication

Kumudhini Preethi Haran, Agnes Hajduczki, Mary S. Pampusch, +6

Frontiers in Immunology

A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge

Kathryn McGuckin Wuertz, Erica K. Barkei, Wei‐Hung Chen, +53

npj Vaccines

Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques

Hannah A. D. King, Michael Joyce, Inès Lakhal-Naouar, +54

Proceedings of the National Academy of Sciences

VaccinationRfn VaccinationVaccine DevelopmentNovel VariantsCross-neutralization Activity +12

Bispecific chimeric antigen receptors targeting the CD4 binding site and high-mannose Glycans of gp120 optimized for anti–human immunodeficiency virus potency and breadth with minimal immunogenicity

Mustafa H. Ghanem, Sara Bolivar-Wagers, Barna Dey, +6

Cytotherapy

Minimal ImmunogenicityHuman RetrovirusImmunodeficienciesGlycobiologyImmunology +11

Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations

Vincent Dussupt, Rajeshwer S. Sankhala, Letzibeth Mendez-Rivera, +43

Nature Immunology

A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein

Michael Joyce, Rajeshwer S. Sankhala, Wei‐Hung Chen, +16

Crystal StructureViral PathogenesisImmunologyMolecular BiologyImmunodominance +18

SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial

Brittany L Ober Shepherd, Paul T Scott, Jack N Hutter, +26

The Lancet Microbe

Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity

Wei‐Hung Chen, Agnes Hajduczki, Elizabeth J. Martinez, +42

Nature Communications

Synthetic VirologyViral PathogenesisImmunologyViral Structural ProteinVirus Transmission +15